Results from randomized controlled trials have indicated that sodium glucose cotransporter 2 (SGLT2) inhibitors lower the chances of major adverse cardiovascular events (MACE). In the trials, MACE was defined as a composite of mortality due to cardiovascular causes, non-fatal MI, or non-fatal stroke. SGLT2 inhibitors also decreased the risk of all-cause mortality and heart failure compared with dipeptidyl peptidase-4 (DPP-4) inhibitors.
These studies have led to the use of select SGLT2 inhibitors as a means to treat heart failure regardless of type 2-diabetes or ejection-fraction status. SGLT2 inhibitors can be used in patients with heart failure with reduced or preserved ejection fraction (i.e., HFrEF, HFpEF). Mechanistically, these agents inhibit the reabsorption of filtered glucose, thus decreasing the risk of future heart-failure decompensation.
What has been your clinical experience with SGLT2 inhibitors in heart failure patients? How does this class compare with other HF agents? Which HF patients are particularly responsive to SGLT2 inhibitors in your experience?
-
Heart Failure Connect4yrThanks, All, for your wonderful responses! How do you compare SGLT2 inhibitors to other treatments for HF? How do you advise your patients on these drugs? Do your patients encounter Show More -
Keith Atassi4yrSGLT2 inhibitor is gaining a huge momentum of my practice , I usually bring patients to office , to discuss the indication , start them on a sample , while Show More
